TILT-123

BIOLOGICAL6 trials

Sponsors

TILT Biotherapeutics Ltd.

Conditions

Head and Neck Squamous Cell CarcinomaLung CancerMelanomaMetastatic MelanomaPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma

Phase 1

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

CompletedNCT04217473

TILT Biotherapeutics Ltd.Metastatic Melanoma

Start: 2020-02-26End: 2024-07-23Updated: 2025-08-07

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

CompletedNCT04695327

TILT Biotherapeutics Ltd.Solid Tumor

Start: 2021-01-11End: 2025-09-03Updated: 2026-03-06

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Active, not recruitingNCT05222932

TILT Biotherapeutics Ltd.Head and Neck Squamous Cell Carcinoma, Melanoma

Start: 2023-03-08End: 2026-12-31Target: 15Updated: 2025-08-07

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

RecruitingNCT05271318

TILT Biotherapeutics Ltd.Platinum-Refractory Fallopian Tube Carcinoma, Platinum-refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma +6

Start: 2022-05-17End: 2027-08-31Target: 29Updated: 2025-11-03

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Active, not recruitingNCT06125197

TILT Biotherapeutics Ltd.Lung Cancer

Start: 2024-07-23End: 2026-05-30Target: 22Updated: 2025-12-23

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

Active, not recruitingNCT06961786

TILT Biotherapeutics Ltd.Metastatic Melanoma

Start: 2025-06-25End: 2027-04-01Target: 9Updated: 2026-03-05

Related Papers

Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumours.

2026-01-20

Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.

Journal of Clinical Oncology2025-05-281 citations

Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.

Journal of Clinical Oncology2025-05-28

Abstract 2035: Clinical-immunological correlates in platinum resistant or refractory ovarian cancer patients treated with chimeric oncolytic adenovirus encoding TNFa and IL-2 (TILT-123) in combination with pembrolizumab

Cancer Research2025-04-21

Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes

Cancer Gene Therapy2025-04-101 citations

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.

2025-02-0510 citations

Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial

Journal for ImmunoTherapy of Cancer2025-01-014 citations

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.

2024-11-0610 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.

Journal of Clinical Oncology2024-06-011 citations

Intravenous delivery of oncolytic adenovirus TILT-123 results in systemic tumor transduction and accumulation of lymphocytes.

Journal of Clinical Oncology2024-06-011 citations

Abstract CT139: Immunological activity of oncolytic adenovirus encoding TNFα and IL-2 (TILT-123) in combination with pembrolizumab in platinum resistant or refractory ovarian cancer patients

Cancer Research2024-04-051 citations

Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Clinical Cancer Research2024-03-2723 citations

1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)

2023-10-312 citations

749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results

Regular and Young Investigator Award Abstracts2023-10-311 citations

711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials

Regular and Young Investigator Award Abstracts2023-10-31

739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial

Regular and Young Investigator Award Abstracts2023-10-31

715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials

Regular and Young Investigator Award Abstracts2022-11-01

First-in-human clinical trial of an oncolytic adenovirus armed with TNFa and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.

Journal of Clinical Oncology2022-06-012 citations

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1

Cells2021-01-2740 citations

1 more papers not shown